Early Intervention in COVID-19: Favipiravir Verses Standard Care

Phase 3 Completed 502 enrolled Chelsea and Westminster NHS Foundation Trust FUJIFILM Toyama Chemical Co., Ltd. · collab Imperial College London · collab NEAT ID Foundation · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Currently we do not know how best to treat patients infected with COVID-19. This study is looking at whether randomising participants to either favipiravir or to usual care, can help patients with suspected or proven COVID-19 infection.

Timeline

Start: 2020-05-01
Primary completion: 2021-06-25
Completion: 2021-06-25

Outcome

Missed primary endpoint

paper There was no significant difference between those who received favipiravir and standard care, relative to those who received standard care alone in time to recovery PMID 36528039 ↗

Publications

Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramirez B, Tonkin J, Santos BR, Cardoso SW, Ritchie AI, Conway F, Riberio MPD, Wiseman DJ, Tana A, Vijayakumar B, Caneja C, Leaper C, Mann B, Samson A, Bhavsar PK, Boffito M, Johnson MR, Pozniak A, Pelly M; PIONEER trial group. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med. 2023 May;11(5):415-424. doi: 10.1016/S2213-2600(22)00412-X. Epub 2022 Dec 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Favipiravir	Small molecule	800 mg	Oral